Meningioma-Medulloblastoma-Ependimoma
Özet
Meningioma, ependimoma ve medulloblastoma, merkezi sinir sistemi (MSS) tümörleri arasında önemli bir yere sahip olup, biyolojik özellikleri ve klinik seyirleri farklılık gösterir. Meningioma genellikle erişkinlerde görülen benign bir tümör iken, ependimoma ve medulloblastoma daha agresif bir seyir izler ve pediatrik yaş grubunda daha sık rastlanır. Tedavide cerrahi, radyoterapi ve kemoterapi gibi multimodal yaklaşımlar uygulanırken, tedavi sonrası sürveyans hastaların uzun dönem sağkalımını artırmak ve yaşam kalitesini korumak açısından büyük önem taşır. Sürveyans, tümör nüksünün erken tespiti, tedaviye bağlı yan etkilerin yönetimi ve genel sağlık durumunun değerlendirilmesi için kritik bir süreçtir. Takip protokolleri tümörün histopatolojik özelliklerine, nüks riskine ve hastanın genel durumuna göre kişiselleştirilir. Meningioma hastalarında düşük nüks riski nedeniyle daha seyrek takip önerilirken, ependimoma ve medulloblastoma gibi yüksek riskli tümörlerde sık ve detaylı bir izleme programı gereklidir. Bu bölümde, üç tümör türüne yönelik optimal sürveyans yaklaşımları, görüntüleme yöntemleri ve takip parametreleri ele alınmıştır. Multidisipliner ekip çalışmaları ve teknolojik yeniliklerle bu süreçlerin daha etkili hale getirilmesi hedeflenmektedir.
Meningioma, ependymoma, and medulloblastoma are significant central nervous system (CNS) tumors with distinct biological characteristics and clinical courses. Meningiomas are typically benign tumors seen in adults, whereas ependymomas and medulloblastomas exhibit more aggressive behavior and are more commonly diagnosed in pediatric populations. While multimodal treatments such as surgery, radiotherapy, and chemotherapy play a key role in managing these tumors, post-treatment surveillance is crucial for improving long-term survival and maintaining quality of life. Surveillance focuses on the early detection of tumor recurrence, management of treatment-related side effects, and overall health assessment. Follow-up protocols are tailored based on the tumor's histopathological features, recurrence risk, and the patient’s clinical condition. Meningiomas, with their lower recurrence risk, usually require less frequent monitoring, while high-risk tumors such as ependymomas and medulloblastomas necessitate intensive and detailed follow-up programs. This section discusses optimal surveillance strategies for these three tumor types, emphasizing imaging techniques, follow-up parameters, and individualized protocols. Multidisciplinary collaboration and advancements in technology aim to enhance the effectiveness and efficiency of surveillance processes, ultimately improving patient outcomes.
Referanslar
Louis, D.N., et al., The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-oncology, 2021. 23(8): p. 1231-1251.
Nabors, B., et al., NCCN CNS tumor guidelines update for 2023. 2023, Oxford University Press US. p. 2114-2116.
Figuracion, K.C.F., et al., Surveillance of long-term complications after treatment of adult brain tumor survivors—review and evidence-based recommendations. Neuro-Oncology Practice, 2022. 9(6): p. 475-486.
Goldbrunner, R., et al., EANO guidelines for the diagnosis and treatment of meningiomas. The Lancet Oncology, 2016. 17(9): p. e383-e391.
Ang, C., et al., Characteristics and outcomes of medulloblastoma in adults. Pediatric blood & cancer, 2008. 51(5): p. 603-607.
Savoor, R., et al., Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases. Journal of Neuro-Oncology, 2021. 151: p. 241-247.
Marosi, C., et al., Meningioma. Critical reviews in oncology/hematology, 2008. 67(2): p. 153-171.
Uduma, U., J. Emejulu, and M. Motah, Intracranial meningiomas in the present era of modern neuroimaging: diagnostic and management options, with radiological illustrations. Orient Journal of Medicine, 2013. 25(3-4): p. 67-74.
McNamara, C., et al., 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology, 2022. 64(10): p. 1919-1950.
Ostrom, Q.T., et al., CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro-oncology, 2022. 24(Supplement_5): p. v1-v95.
Perry, A., et al., “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1999. 85(9): p. 2046-2056.
Pasquier, D., et al., Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. International Journal of Radiation Oncology* Biology* Physics, 2008. 71(5): p. 1388-1393.
Yang, S.-Y., et al., Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. Journal of Neurology, Neurosurgery & Psychiatry, 2008. 79(5): p. 574-580.
Marciscano, A.E., et al., Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. Journal of neurosurgery, 2016. 124(1): p. 106-114.
Oya, S., et al., Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. Journal of neurosurgery, 2012. 117(1): p. 121-128.
Recker, M.J., et al., Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018. Journal of Neuro-Oncology, 2022. 160(1): p. 13-22.
Maier, A.D., et al., Clinical and histopathological predictors of outcome in malignant meningioma. Neurosurgical Review, 2020. 43: p. 643-653.
Postalci, L., et al., Spinal meningiomas: recurrence in ventrally located individuals on long-term follow-up; a review of 46 operated cases. Turkish neurosurgery, 2011. 21(4).
Bos, D., et al., Prevalence, clinical management, and natural course of incidental findings on brain MR images: the population-based Rotterdam Scan Study. Radiology, 2016. 281(2): p. 507-515.
Nakamura, M., et al., The natural history of incidental meningiomas. Neurosurgery, 2003. 53(1): p. 62-71.
Olivero, W.C., J.R. Lister, and P.W. Elwood, The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. Journal of neurosurgery, 1995. 83(2): p. 222-224.
Rahatli, F.K., et al., Can unenhanced brain magnetic resonance imaging be used in routine follow up of meningiomas to avoid gadolinium deposition in brain? Clinical imaging, 2019. 53: p. 155-161.
Nakamura, M., et al., Long-term surgical outcomes of spinal meningiomas. Spine, 2012. 37(10): p. E617-E623.
Garzon-Muvdi, T., et al., Atypical and anaplastic meningioma: outcomes in a population based study. Journal of neuro-oncology, 2017. 133: p. 321-330.
Champeaux, C. and L. Dunn, World Health Organization grade II meningioma: a 10-year retrospective study for recurrence and prognostic factor assessment. World Neurosurgery, 2016. 89: p. 180-186.
de Almeida, A.N., et al., Clinical outcome, tumor recurrence, and causes of death: a long-term follow-up of surgically treated meningiomas. World neurosurgery, 2017. 102: p. 139-143.
Roth, P., et al., Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Annals of Oncology, 2021. 32(2): p. 171-182.
Islim, A.I., et al., Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. Journal of neuro-oncology, 2019. 142: p. 211-221.
Islim, A.I., et al., A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro-oncology, 2020. 22(2): p. 278-289.
Goldbrunner, R., et al., EANO guideline on the diagnosis and management of meningiomas. Neuro-oncology, 2021. 23(11): p. 1821-1834.
Yano, S. and J.-i. Kuratsu, Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. Journal of neurosurgery, 2006. 105(4): p. 538-543.
Sofela, A.A., et al., Biomarkers for differentiating grade II meningiomas from grade I: A systematic review. British Journal of Neurosurgery, 2021. 35(6): p. 696-702.
Galani, V., et al., Genetic and epigenetic alterations in meningiomas. Clinical neurology and neurosurgery, 2017. 158: p. 119-125.
Cordova, C. and S.C. Kurz, Advances in molecular classification and therapeutic opportunities in meningiomas. Current Oncology Reports, 2020. 22: p. 1-10.
Pekic, S., D. Miljic, and V. Popovic, Hypopituitarism following cranial radiotherapy. 2018.
van Nieuwenhuizen, D., et al., Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. Journal of neuro-oncology, 2007. 84: p. 271-278.
Timmer, M., et al., Long-term outcome and health-related quality of life of elderly patients after meningioma surgery. World neurosurgery, 2019. 125: p. e697-e710.
Wong, J.M., et al., Patterns in neurosurgical adverse events: intracranial neoplasm surgery. Neurosurgical focus, 2012. 33(5): p. E16.
Franceschi, E., et al., Adult medulloblastoma: updates on current management and future perspectives. Cancers, 2022. 14(15): p. 3708.
Korshunov, A., et al., Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. Journal of clinical oncology, 2010. 28(18): p. 3054-3060.
Abacioglu, U., et al., Medulloblastoma in adults: treatment results and prognostic factors. International Journal of Radiation Oncology* Biology* Physics, 2002. 54(3): p. 855-860.
Chan, A.W., et al., Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery, 2000. 47(3): p. 623-632.
Padovani, L., et al., Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. International Journal of Radiation Oncology* Biology* Physics, 2007. 68(2): p. 433-440.
Horbinski, C., et al., NCCN guidelines® insights: central nervous system cancers, version 2.2022: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 2023. 21(1): p. 12-20.
Franceschi, E., et al., EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. The Lancet Oncology, 2019. 20(12): p. e715-e728.
Escudero, L., et al., Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nature communications, 2020. 11(1): p. 5376.
Verheul, C., A. Kleijn, and M.L. Lamfers, Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. Handbook of clinical neurology, 2018. 146: p. 139-169.
Seidel, C., et al., Radiotherapy in medulloblastoma—evolution of treatment, current concepts and future perspectives. Cancers, 2021. 13(23): p. 5945.
De, B., et al., Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. Journal of neuro-oncology, 2018. 136: p. 95-104.
Duffner, P.K., Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. The neurologist, 2004. 10(6): p. 293-310.
Kocakaya, S., C.P. Beier, and D. Beier, Chemotherapy increases long-term survival in patients with adult medulloblastoma—a literature-based meta-analysis. Neuro-oncology, 2015. 18(3): p. 408-416.
Brandes, A.A., et al., Long‐term results of a prospective study on the treatment of medulloblastoma in adults. Cancer, 2007. 110(9): p. 2035-2041.
Ostrom, Q.T., et al., CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-oncology, 2021. 23(Supplement_3): p. iii1-iii105.
Rudà, R., et al., EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-oncology, 2018. 20(4): p. 445-456.
Kawabata, Y., et al., Long-term outcome in patients harboring intracranial ependymoma. Journal of neurosurgery, 2005. 103(1): p. 31-37.
Rodríguez, D., et al., Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973–2005). Journal of Surgical Research, 2009. 156(2): p. 340-351.
Brandes, A.A., et al., A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia. Cancer, 2005. 104(1): p. 143-148.
Gornet, M., et al., Chemotherapy for advanced CNS ependymoma. Journal of neuro-oncology, 1999. 45: p. 61-67.
Wienecke, R., et al., Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 1997. 42(2): p. 230-235.
Marinoff, A.E., et al., Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. Journal of neuro-oncology, 2017. 135: p. 201-211.
Smith, A., et al., EPEN-54. ACNS0831, phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years. Neuro-oncology, 2020. 22(Supplement_3): p. iii318-iii319.
Merchant, T.E. and M. Fouladi, Ependymoma: new therapeutic approaches including radiation and chemotherapy. Journal of neuro-oncology, 2005. 75: p. 287-299.
Armstrong, T.S., E. Vera‐Bolanos, and M.R. Gilbert, Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer, 2011. 117(22): p. 5133-5141.
Plotkin, S.R., et al., Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. Journal of Neurosurgery: Spine, 2011. 14(4): p. 543-547.
Au, K.-S., et al., Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. Journal of child neurology, 2004. 19(9): p. 699-709.
Larrew, T., et al., Molecular classification and therapeutic targets in ependymoma. Cancers, 2021. 13(24): p. 6218.
Han, Y.-P., H.-W. Lin, and H. Li, Cancer Stem Cells in Tumours of the Central Nervous System in Children: A Comprehensive Review. Cancers, 2023. 15(12): p. 3154.
